Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Clinical trial NCT04084717 · COMPLETED

Trial details

NCT number: NCT04084717
Sponsor: University Health Network, Toronto
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small-cell Lung Cancer Stage IV Non-small Cell Lung Cancer ROS1 Gene Rearrangement MET Activating Mutation MET Amplification

Start date: 2019-12-03
Primary completion: 2024-12-30
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.